Update in Diffuse Parenchymal Lung Disease 2013
Rosas IO, Kaminski N. Update in Diffuse Parenchymal Lung Disease 2013. American Journal Of Respiratory And Critical Care Medicine 2015, 191: 270-274. PMID: 25635490, PMCID: PMC4351573, DOI: 10.1164/rccm.201405-0856up.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalClinical Trials, Phase III as TopicDisease ProgressionDrug ApprovalEnzyme InhibitorsGenomicsHumansIdiopathic Pulmonary FibrosisIndolesLung Diseases, InterstitialPolymorphism, GeneticPyridonesTreatment OutcomeUnited StatesUnited States Food and Drug AdministrationConceptsMajority of patientsDistinct clinical presentationsSignificant clinical implicationsClinical presentationPulmonary fibrosis researchDisease progressionClinical implicationsGenetic biomarkersPatientsFibrosis researchGenetic variantsBiological mechanismsIPFNew biological mechanismsNintedanibPirfenidonePeriodHistoric approvalPalliative Care and Location of Death in Decedents With Idiopathic Pulmonary Fibrosis
Lindell KO, Liang Z, Hoffman LA, Rosenzweig MQ, Saul MI, Pilewski JM, Gibson KF, Kaminski N. Palliative Care and Location of Death in Decedents With Idiopathic Pulmonary Fibrosis. CHEST Journal 2015, 147: 423-429. PMID: 25187973, PMCID: PMC4314817, DOI: 10.1378/chest.14-1127.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisLocation of deathPalliative care referralPalliative careCare referralPulmonary fibrosisAdequacy of endCommunity hospital wardsLung transplant recipientsTiming of referralMajority of patientsObituary listingsTransplant recipientsMedian survivalSymptom burdenSpecialty centersFirst visitHospital settingCenter visitsHospital wardsClinical practiceReferralPatientsDecedentsCare